1 citations
,
June 2001 in “Annals of Internal Medicine” The conclusion is that maintaining blinding in clinical trials is crucial for reliable results.
8 citations
,
May 2019 in “Journal of dermatological treatment” Vismodegib is effective for basal cell carcinoma but has severe side effects.
2 citations
,
January 2014 in “Advanced Biomedical Research” Oral isotretinoin and cyproterone compound are equally effective for treating acne in women with cutaneous hyperandrogenism.
May 2018 in “Journal of Clinical Oncology” The treatment is safe and shows promise for metastatic breast cancer.
March 2020 in “Section 5: Patient safety and quality assurance” Tofacitinib and baricitinib had an acceptable level of side effects in rheumatoid arthritis patients.
January 2026 in “http://isrctn.com/” The food supplement may help reduce hair shedding and improve hair growth.
3 citations
,
June 2020 in “Journal of Dermatological Treatment” Triamcinolone acetonide is slightly more effective than betamethasone for hair regrowth in localized alopecia areata.
3 citations
,
October 2022 in “Clinical, Cosmetic and Investigational Dermatology” The 532 nm laser effectively reduces facial vascular and pigmented lesions, with the VISIA system reliably assessing treatment results.
1 citations
,
September 1981 in “PubMed” Cyproterone acetate effectively treats virilized women, especially under 35, despite some side effects.
9 citations
,
April 2010 in “Lung cancer” Combining gemcitabine with paclitaxel is more effective than with pemetrexed for advanced lung cancer.
April 2026 in “Clinical and Translational Science” Tofacitinib effectively treats severe alopecia areata, improving hair regrowth and patient satisfaction.
17 citations
,
January 2019 in “Dermatologic Therapy” Tofacitinib is effective and safe for long-term treatment of severe alopecia areata, with many patients achieving complete hair regrowth.
July 2025 in “SKIN The Journal of Cutaneous Medicine” Ritlecitinib is generally safe for alopecia areata patients over 72 months.
44 citations
,
May 2023 in “MedComm” PROTAC technology shows promise for cancer treatment but needs more effective E3 ligase recruiters.
August 2010 in “The Journal of Dermatology” The document concludes that low-dose acne treatment is most suitable for moderate acne, with high patient satisfaction and low relapse rates.
24 citations
,
December 2020 in “Kardiologiia” Bromhexine and spironolactone together reduced COVID-19 symptoms and hospitalization time without side effects.
15 citations
,
December 2009 in “PubMed” A child with eruptive vellus hair cysts showed some improvement with calcipotriene cream.
September 2022 in “Journal of the American Academy of Dermatology” The registry showed that tofacitinib is promising for treating hair loss in children with alopecia areata, but more research is needed.
1 citations
,
January 2026 in “International Journal of Dermatology” Amivantamab can cause severe skin eruptions and scarring, requiring drug discontinuation and early treatment.
1 citations
,
January 1999 in “The European journal of contraception & reproductive health care” Valette® is an effective birth control pill that also reduces greasy hair and skin.
18 citations
,
December 2015 in “PubMed” Intralesional triamcinolone is more effective than topical betamethasone for treating localized alopecia areata.
August 2010 in “Oncology Times” Provenge extends prostate cancer survival by about 4 months.
February 2017 in “Cancer Research” Topical calcitriol appears safe and may reduce hair loss during chemotherapy.
November 2020 in “Journal of The American Academy of Dermatology” Certain immune markers may predict chemotherapy response in mesothelioma, and nivolumab is a tolerable and effective treatment for advanced non-small cell lung cancer.
28 citations
,
August 1981 in “Journal of the American Academy of Dermatology” Retinoic acid is effective for treating eruptive vellus hair cysts.
1 citations
,
August 2021 in “Journal of The American Academy of Dermatology” Baricitinib helped improve hair, eyebrow, and eyelash growth in alopecia areata patients.
2 citations
,
September 2022 in “Dermatologic Therapy” Tofacitinib is a promising treatment for severe alopecia areata, with many patients experiencing complete or partial hair regrowth.
41 citations
,
February 2021 in “Cureus” Dutasteride treatment in men with mild to moderate COVID-19 reduced viral shedding, inflammation, and recovery time without serious side effects.
December 2022 in “Pakistan Journal of Medical and Health Sciences” Tofacitinib effectively treats Alopecia Areata.
The 0.05% dutasteride topical solution effectively promotes hair growth with fewer side effects than oral treatments.